KARA WARSHAW: Open Payments
NPI 1942290200 · SULPHUR, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,309 in 139 payments from 15 companies in 2025. Trend: 2023 $517 · 2024 $1,117 · 2025 $2,309
Food & beverage: $2,297Education: $12
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 26 | $383 |
| Alkermes, Inc. | 23 | $323 |
| Neurocrine BioSciences, Inc. | 13 | $322 |
| ABBVIE INC. | 21 | $290 |
| Vanda Pharmaceuticals Inc. | 12 | $204 |
| Teva Pharmaceuticals USA, Inc. | 11 | $158 |
| Axsome Therapeutics, Inc. | 10 | $139 |
| Janssen Pharmaceuticals, Inc | 4 | $91 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $89 |
| E.R. Squibb & Sons, L.L.C. | 3 | $70 |
Products named: INGREZZA, VRAYLAR, ARISTADA, REXULTI, FANAPT, Auvelity, ABILIFY ASIMTUFII, CAPLYTA.
Industry payments across LA — which companies pay providers there.
